Acquisitions, Investments, and Licenses - Textual (Details)	3 Months Ended	9 Months Ended			1 Months Ended		1 Months Ended	3 Months Ended	1 Months Ended		3 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended	0 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended	1 Months Ended		0 Months Ended	1 Months Ended					0 Months Ended		0 Months Ended			1 Months Ended	9 Months Ended
	Sep. 30, 2013 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2012 USD ($)	Dec. 31, 2012 USD ($)	Jun. 30, 2012 SciVac [Member] Variable Interest Entity, Primary Beneficiary [Member] USD ($) member	Sep. 30, 2013 SciVac [Member] Variable Interest Entity, Primary Beneficiary [Member] USD ($)	Aug. 31, 2011 Neovasc [Member] USD ($)	Sep. 30, 2013 Neovasc [Member] USD ($)	Apr. 30, 2013 Pharmsynthez [Member] USD ($)	Apr. 30, 2013 Pharmsynthez [Member] RUB	Sep. 30, 2013 Pharmsynthez [Member] USD ($)	Sep. 30, 2013 Pharmsynthez [Member] USD ($)	Mar. 31, 2013 RXi Pharmaceuticals Corporation [Member] USD ($)	Sep. 30, 2013 RXi Pharmaceuticals Corporation [Member] USD ($)	Aug. 29, 2013 PROLOR [Member] USD ($)	Sep. 30, 2013 PROLOR [Member] USD ($)	Mar. 31, 2013 Cytochroma acquisition [Member] USD ($)	Sep. 30, 2013 Cytochroma acquisition [Member] USD ($)	Feb. 28, 2013 OPKO Brazil [Member] USD ($)	Dec. 31, 2012 OURLab [Member] USD ($)	Aug. 29, 2013 Farmadiet Acquisition [Member]	Aug. 31, 2013 Farmadiet Acquisition [Member] USD ($)	Aug. 31, 2012 Farmadiet Acquisition [Member] USD ($) Transaction	Aug. 31, 2012 Farmadiet Acquisition [Member] EUR (€)	Sep. 30, 2013 Farmadiet Acquisition [Member] USD ($)	Sep. 30, 2013 Farmadiet Acquisition [Member] EUR (€)	Aug. 29, 2013 Farmadiet Acquisition [Member] Ancillary Transaction One [Member]	Aug. 31, 2012 Farmadiet Acquisition [Member] Ancillary Transaction One [Member]	Aug. 29, 2013 Farmadiet Acquisition [Member] Ancillary Transaction Two [Member] USD ($)	Aug. 29, 2013 Farmadiet Acquisition [Member] Ancillary Transaction Two [Member] EUR (€)	Aug. 31, 2012 Farmadiet Acquisition [Member] Ancillary Transaction Two [Member] USD ($)	Aug. 31, 2012 ALS Acquisition [Member] USD ($)	Sep. 30, 2013 ALS Acquisition [Member] USD ($)	Apr. 30, 2012 ALS Acquisition [Member] USD ($)
Business Acquisition [Line Items]
Shares conversion ratio															0.9951
Delivery of common stock															63,670,805		20,517,030		64,684	7,072,748		585,703					125,000		70,421	70,421
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned															$ 540,600,000		$ 146,900,000		$ 400,000	$ 32,900,000											$ 300,000
Share price															$ 8.49	$ 8.49	$ 7.16		$ 6.73	$ 4.65					$ 7.52
Options and warrants outstanding (shares)															7,889,265
Fair value of warrants outstanding															46,100,000
Percentage of ownership held by chairman															5.00%
Percentage of ownership held by directors															5.00%
Number of trading days																	10 days		10 days	15 days	10 days	10 days
Business acquisition share price on shares issue																	$ 4.87		$ 4.64	$ 4.33		$ 7.61
Amount payable in cash or shares on achieving milestones for acquiring a product in development																	190,000,000.0														1,000,000.0
Contingent consideration	69,200,000	69,200,000		20,000,000													47,700,000						1,200,000
Cash paid at closing date					700,000														300,000	9,400,000			8,400,000									2,400,000	800,000
Aggregate purchase price																							16,000,000	13,500,000					1,300,000	1,000,000		4,000,000
Stock consideration issued in the transaction is being held in a separate escrow account to secure the indemnification obligations of OURLab																				1,732,102
Cash paid at closing date percentage																							50.00%	50.00%							25.00%
Percentage of deferred payment paid at our option in cash or shares																							50.00%	50.00%
Percentage of paid on first anniversary of closing date																							25.00%	25.00%
Paid in eighteen months after closing date in percentage																							25.00%	25.00%
Deferred acquisition payments	5,335,000	5,335,000		6,172,000																			7,800,000	6,800,000
Deferred acquisition payments discount																							600,000
Deferred Payment to satisfy indemnify claims																									3,600,000	2,800,000
Number of ancillary transactions																							2	2
Percentage for ancillary transaction																											40.00%
Issue of common stock / Issue of common stock against acquisition																												250,000
Number of shares issued upon achieving certain milestone																												125,000
Percentage of amount payable on cash or shares on achieving certain milestone																															75.00%
Purchase Consideration in cash at closing into a separate escrow account																																		800,000
Net loss																2,500,000		15,600,000
Invested in common shares							2,000,000	1,200,000						2,500,000
Number of shares purchased							2,000,000		13,600,000	13,600,000			17,241,380
Warrants expiration period							2 years
Warrants to purchase common shares							1,000,000
Investment Warrants, Exercise Price							$ 1.25
Asset Purchase Agreement									9,600,000
Number of share options received in purchase agreement									12,000,000	12,000,000
Deferred revenue	7,900,000	7,900,000		1,900,000					9,500,000
Proceeds to be received from sale of proprietary technology									8,100,000	265,000,000
Period for development of technology									3 years	3 years
Proceeds from collection of notes feceivable											0
Deferred revenue received from collaboration agreement	3,400,000											6,800,000
Revenue related to our license agreements											1,300,000	3,200,000
Revenue collaboration agreement, offset to research and development	400,000	700,000
Issue of common stock shares													50,000,000
Revenue related to sale of intellectual property		12,500,000	0											12,500,000
Milestone payments													50,000,000.0
Asset purchase agreement financing for Rxi														16,400,000
Cocrystal on a fully diluted basis					45.00%
Additional working capital						1,800,000
Number of members of board of directors					5
Number of members of board of directors appointed by reporting entity					3
Percent of board of directors appointed by reporting entity					60.00%
Total assets of equity method investees	105,500,000	105,500,000
Total liabilities of equity method investees	39,600,000	39,600,000
Net losses of equity method investees		$ (51,200,000)